AIM
CRL icon

Acrospire Investment Management’s Charles River Laboratories CRL Stock Holding History

Acrospire Investment Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-600
Closed -$61K – 329
2017
Q2 		$61K Sell
600
-1,000
-63% -$92K 0.06% 669
2017
Q1 		$144K Sell
1,600
-300
-16% -$25.5K 0.12% 136
2016
Q4 		$145K Buy
1,900
+300
+19% +$22.8K 0.06% 641
2016
Q3 		$133K Sell
1,600
-800
-33% -$67.1K 0.09% 341
2016
Q2 		$198K Sell
2,400
-1,900
-44% -$156K 0.15% 85
2016
Q1 		$327K Buy
+4,300
New +$318K 0.23% 11

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acrospire Investment Management's CRL Position: Q3 2017 in Review

Acrospire Investment Management sold out of Charles River Laboratories (CRL) in Q3 2017, closing a stake of 600 shares — an estimated $61K sold.

Acrospire Investment Management first reported a position in CRL in Q1 2016 and held it in 6 quarters. The position peaked at $327K in Q1 2016. 336 funds tracked by Wall St. Rank hold CRL as of Q3 2017.

  • Acrospire Investment Management reported no remaining Charles River Laboratories position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 600 Charles River Laboratories shares in Q3 2017, an estimated $61K.
  • Acrospire Investment Management first reported a position in Charles River Laboratories in Q1 2016 and held it in 6 quarters.
  • Acrospire Investment Management's Charles River Laboratories position peaked at $327K in Q1 2016.
  • 336 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.